News & Updates
Filter by Specialty:
Novel IL-17A inhibitor helps dial down psoriatic arthritis disease activity
Potent and selective inhibition of IL-17A by izokibep produced a rapid improvement in disease activity across multiple psoriatic arthritis (PsA) domains, according to preliminary data from a phase IIb/III trial.
Novel IL-17A inhibitor helps dial down psoriatic arthritis disease activity
17 Jul 2024
Upadacitinib proves long-term efficacy in RA
Upadacitinib remains effective through 5 years in patients with rheumatoid arthritis (RA) who have inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), with no new safety signals, as shown by the results of the phase III long-term extension (LTE) of SELECT-NEXT.
Upadacitinib proves long-term efficacy in RA
17 Jul 2024
Tofacitinib shows good retention rates in PsA patients
Tofacitinib demonstrates safety and persistence in patients with psoriatic arthritis (PsA) who are mostly refractory to biologic and oral targeted synthetic disease-modifying antirheumatic drugs, results of a study have shown.
Tofacitinib shows good retention rates in PsA patients
15 Jul 2024
Statin use tied to joint replacement risk
A French study presented at EULAR 2024 reveals an association between statin treatment and an increased risk of total joint replacement in individuals with knee and hip osteoarthritis (OA).
Statin use tied to joint replacement risk
11 Jul 2024
Rituximab shows promise in management of neuropsychiatric SLE
Treatment with rituximab (RTX) in patients with moderate-to-severe neuropsychiatric (NP) systemic lupus erythematosus (SLE) appears to result in some improvements and to contribute to the use of a much lower steroid dose at 6 months, suggests a study presented at EULAR 2024.